Developer docs
API playgroundTry for free, no card

Search company profiles

Outpace Bio

Full company profile

uuid0000ip2

Namestring
Outpace Bio
Legal namestring
Outpace Bio, Inc.
Websiteurl
outpacebio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Outpace Bio is a Seattle-based clinical-stage biotechnology company founded in 2021 as a spin-out from Lyell Immunopharma. The company develops AI-powered engineered T cell therapies intended to overcome barriers to curing solid tumors, which account for more than 90% of cancer cases but have seen limited cell therapy efficacy to date. Its technology platform is built around de novo protein design, combining proprietary machine learning algorithms with biological knowledge to generate novel proteins that program immune cell function inside patients. The platform comprises five modular technology stacks: OUTSPACER (optimized CAR libraries), OUTSMART (designed cytokines for tumor-localized immune activation), OUTLAST (T cell persistence regulation), OUTSAFE/EGFRopt (cetuximab-responsive safety switches), and CoLOCKR logic-gated targeting (Boolean antigen recognition). These modules can be combined into single cell therapy products, as demonstrated by lead program OPB-101, an autologous mesothelin CAR-T for ovarian cancer and other solid tumors currently in early clinical stage, and pipeline programs OPB-201 (PRAME TCR-T for endometrial cancer, IND-enabling) and OPB-301 (undisclosed).

The company generates no commercial revenue and distributes investigational therapies exclusively through clinical trial participation. Future revenue is expected from commercialization of approved cell therapy products and potentially from platform licensing, though pricing has not been disclosed. Outpace has raised approximately $199 million across three venture rounds (Series A 2021, Series A extension 2023, Series B 2024), led by RA Capital, ARTIS Ventures, and Lyell Immunopharma with participation from Bristol-Myers Squibb, Mubadala, and Qatar Investment Authority. Strategic partnerships with Lyell Immunopharma (IL-12 co-development), UW Institute for Protein Design (David Baker lab), Fred Hutch Cancer Center (Stan Riddell), Memorial Sloan Kettering, and the University of North Carolina anchor the company's research and translation capabilities, alongside its founding membership in the OpenFold AI Research Consortium.

Short descriptiontext

Outpace Bio is a Seattle-based clinical-stage biotechnology company that uses AI-powered protein design to develop engineered T cell therapies for solid tumors, with lead program OPB-101 in early clinical development for ovarian cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy development, AI protein design, cancer immunotherapy, engineered T cells, solid tumor therapy
Industry2 codes
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAAABAJ
Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Cell Therapy Biotechnology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Product Development
TypeOne Time License
Description

Pre-revenue biotech company developing engineered T cell therapies for solid tumors. Revenue will be generated through commercialized cell therapy products following regulatory approval

outpacebio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Outpace Bio is a clinical-stage biotechnology company that uses AI-powered protein design to create engineered T cell therapies for solid tumors. The company combines five modular platform technologies (OUTSPACER, OUTSMART, OUTLAST, OUTSAFE/EGFRopt, and Logic Gated Targeting/CoLOCKR) into single cell therapy products, with lead program OPB-101 (mesothelin CAR-T) advancing through early clinical development for ovarian cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 50,000 novel proteins can be generated in under three days
+1 more record
Product overview1 text field

Outpace Bio is a biotechnology company that has developed an AI-powered protein design platform for cell therapy. The platform consists of five core technology modules—OUTSPACER™ (optimized CAR library), OUTSMART™ (designed cytokines), OUTLAST™ (T cell persistence), OUTSAFE™/EGFRopt™ (safety switches), and Logic Gated Targeting—these can be combined into single cell therapy products with curative potential. The company is applying these technologies to build a pipeline of engineered T cell therapies, with lead program OPB-101 (mesothelin CAR-T) in early clinical stage for ovarian cancer and solid tumors. Outpace Bio operates as a spinout from Lyell Immunopharma, co-founded in 2021, and is headquartered in Seattle, Washington.

Product and service3 records
1OPB-101
CategoryCell Therapy Product
Description

Autologous mesothelin (MSLN)-specific CAR-T therapy in development for ovarian cancer and other solid tumors; combines Outpace's OUTSPACER, OUTSMART, OUTLAST, and OUTSAFE technologies to address tumor immune suppression, persistence, potency, safety, and specificity challenges.

2OPB-201
CategoryCell Therapy Product
Description

TCR-T cell therapy targeting PRAME for endometrial cancer and other solid tumors, currently in IND-enabling stage.

3OPB-301
CategoryCell Therapy Product
Description

Undisclosed cell therapy program in Outpace's pipeline; stage not publicly disclosed.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Outpace Bio is a founding member of OpenFold, the leading consortium for AI-powered protein research. The consortium supports open-access development of protein folding and design software for use by a wide community of researchers to discover new medicines.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Outpace and Lyell are collaborating to unlock the biology of IL-12, a cytokine that has potential to dramatically improve efficacy in treating patients with cancer but requires careful control to avoid systemic toxicity. Lyell was also an original investor in Outpace Bio.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Outpace collaborates with David Baker at the University of Washington Institute for Protein Design to access new machine learning algorithms for protein design capabilities. Baker's lab pioneered the ability to create new biological functions with de novo protein design.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Outpace collaborates with Stanley Riddell at Fred Hutch Cancer Center, a leading expert in adoptive T cell therapy. Riddell co-designed the CD19-specific CAR used in trials that led to FDA-approved Breyanzi.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Prasad Adusumilli at MSKCC focused on solid tumor immunology and T-cell mediated immunotherapy development, particularly for thoracic malignancies and mesothelioma.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Gianpietro Dotti at UNC Lineberger Comprehensive Cancer Center Immunotherapy Program, focusing on developing CAR-T cells for solid tumor treatment.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lyell is Outpace's former parent company and current co-development partner on IL-12 cytokines. Both are clinical-stage cell therapy companies focused on solid tumors, sharing founding-team lineage and overlapping technology approaches to T cell persistence and exhaustion.

TypeDirect peer
Description

Iovance is the leading commercial-stage tumor-infiltrating lymphocyte (TIL) therapy company for solid tumors, with FDA-approved Amtagvi for melanoma. It is the most relevant commercial benchmark for Outpace's solid tumor cell therapy ambitions and shares the autologous cell therapy manufacturing model.

TypeDirect peer
Description

Adaptimmune develops engineered TCR-T cell therapies for solid tumors, with approved Tecelra for synovial sarcoma. Its SPEAR T-cell platform directly competes with Outpace's TCR-T program OPB-201 and shares the same solid tumor cell therapy development pathway.

TypeDirect peer
Description

Allogene is a clinical-stage allogeneic CAR-T developer pursuing both hematologic and solid tumor indications. It is a comparable cell therapy developer with similar funding profile, clinical-stage pipeline, and focus on engineering T cells for cancer.

TypeDirect peer
Description

Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing for hematologic malignancies and solid tumors. As a clinical-stage engineered cell therapy company with similar funding trajectory, it is a directly comparable peer in modality and stage.

TypeDirect peer
Description

Fate Therapeutics develops off-the-shelf iPSC-derived NK and T cell therapies for cancer. Its engineered cell therapy pipeline and use of novel protein engineering approaches (chimeric antigen receptors, antigen receptors) make it a directly comparable peer in modality and platform strategy.

TypeDirect peer
Description

Sana Biotechnology is a clinical-stage cell therapy company developing both allogeneic CAR-T and in vivo gene editing approaches. Outpace's CSO Aaron Foster joined from Sana, and both companies share the engineering-driven approach to next-generation cell therapies.

TypeBroad incumbent
Description

CRISPR Therapeutics is a clinical-stage gene editing company with the first FDA-approved CRISPR-based therapy (Casgevy) and a deep cell therapy pipeline. It is a broader, more advanced incumbent in the engineered cell therapy space with overlapping platform technologies.

9Bellicum Pharmaceuticals
TypeDirect peer
Description

Bellicum developed GoCAR-T cell therapies for solid tumors with proprietary safety switches, sharing Outpace's emphasis on engineered safety controls and solid tumor focus. Several Outpace executives came from Bellicum, and the platforms address overlapping challenges.

10Arsenal Biosciences
TypeEmerging player
Description

Arsenal Bio is a privately-held cell therapy company developing engineered T cell therapies for solid tumors using synthetic biology and machine learning. It is an emerging peer with overlapping platform ambitions in programmable cell therapy for cancer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Outpace Bio

Cancer Cell Therapy Biotechnologyoutpacebio.com

Outpace Bio is a Seattle-based clinical-stage biotechnology company that uses AI-powered protein design to develop engineered T cell therapies for solid tumors, with lead program OPB-101 in early clinical development for ovarian cancer.

What Outpace Bio does

Outpace Bio is a Seattle-based clinical-stage biotechnology company founded in 2021 as a spin-out from Lyell Immunopharma. The company develops AI-powered engineered T cell therapies intended to overcome barriers to curing solid tumors, which account for more than 90% of cancer cases but have seen limited cell therapy efficacy to date. Its technology platform is built around de novo protein design, combining proprietary machine learning algorithms with biological knowledge to generate novel proteins that program immune cell function inside patients. The platform comprises five modular technology stacks: OUTSPACER (optimized CAR libraries), OUTSMART (designed cytokines for tumor-localized immune activation), OUTLAST (T cell persistence regulation), OUTSAFE/EGFRopt (cetuximab-responsive safety switches), and CoLOCKR logic-gated targeting (Boolean antigen recognition). These modules can be combined into single cell therapy products, as demonstrated by lead program OPB-101, an autologous mesothelin CAR-T for ovarian cancer and other solid tumors currently in early clinical stage, and pipeline programs OPB-201 (PRAME TCR-T for endometrial cancer, IND-enabling) and OPB-301 (undisclosed).

The company generates no commercial revenue and distributes investigational therapies exclusively through clinical trial participation. Future revenue is expected from commercialization of approved cell therapy products and potentially from platform licensing, though pricing has not been disclosed. Outpace has raised approximately $199 million across three venture rounds (Series A 2021, Series A extension 2023, Series B 2024), led by RA Capital, ARTIS Ventures, and Lyell Immunopharma with participation from Bristol-Myers Squibb, Mubadala, and Qatar Investment Authority. Strategic partnerships with Lyell Immunopharma (IL-12 co-development), UW Institute for Protein Design (David Baker lab), Fred Hutch Cancer Center (Stan Riddell), Memorial Sloan Kettering, and the University of North Carolina anchor the company's research and translation capabilities, alongside its founding membership in the OpenFold AI Research Consortium.

Outpace Bio firmographics

Firmographics
Name
Outpace Bio
Legal name
Outpace Bio, Inc.
Website
https://outpacebio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Outpace Bio is a Seattle-based clinical-stage biotechnology company that uses AI-powered protein design to develop engineered T cell therapies for solid tumors, with lead program OPB-101 in early clinical development for ovarian cancer.
Ownership category
akta.pro rank

Where Outpace Bio is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Outpace Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Cell Therapy Product Development: Pre-revenue biotech company developing engineered T cell therapies for solid tumors. Revenue will be generated through commercialized cell therapy products following regulatory approval

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Outpace Bio product offering

Product offering

Core offering

Outpace Bio is a clinical-stage biotechnology company that uses AI-powered protein design to create engineered T cell therapies for solid tumors. The company combines five modular platform technologies (OUTSPACER, OUTSMART, OUTLAST, OUTSAFE/EGFRopt, and Logic Gated Targeting/CoLOCKR) into single cell therapy products, with lead program OPB-101 (mesothelin CAR-T) advancing through early clinical development for ovarian cancer.

Product overview

Outpace Bio is a biotechnology company that has developed an AI-powered protein design platform for cell therapy. The platform consists of five core technology modules—OUTSPACER™ (optimized CAR library), OUTSMART™ (designed cytokines), OUTLAST™ (T cell persistence), OUTSAFE™/EGFRopt™ (safety switches), and Logic Gated Targeting—these can be combined into single cell therapy products with curative potential. The company is applying these technologies to build a pipeline of engineered T cell therapies, with lead program OPB-101 (mesothelin CAR-T) in early clinical stage for ovarian cancer and solid tumors. Outpace Bio operates as a spinout from Lyell Immunopharma, co-founded in 2021, and is headquartered in Seattle, Washington.

Differentiator

Problem solved

Functional benefit

Products and services

  • OPB-101 Autologous mesothelin (MSLN)-specific CAR-T therapy in development for ovarian cancer and other solid tumors; combines Outpace's OUTSPACER, OUTSMART, OUTLAST, and OUTSAFE technologies to address tumor immune suppression, persistence, potency, safety, and specificity challenges.
  • OPB-201 TCR-T cell therapy targeting PRAME for endometrial cancer and other solid tumors, currently in IND-enabling stage.
  • OPB-301 Undisclosed cell therapy program in Outpace's pipeline; stage not publicly disclosed.

Quantifiable outcome

  • Over 50,000 novel proteins can be generated in under three days
  • +1 more outcomes

Companies that use Outpace Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Outpace Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Outpace Bio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • OpenFold ConsortiumcoreStrategic or Co-development PartnerOutpace Bio is a founding member of OpenFold, the leading consortium for AI-powered protein research. The consortium supports open-access development of protein folding and design software for use by a wide community of researchers to discover new medicines.
  • Lyell ImmunopharmacoreStrategic or Co-development PartnerOutpace and Lyell are collaborating to unlock the biology of IL-12, a cytokine that has potential to dramatically improve efficacy in treating patients with cancer but requires careful control to avoid systemic toxicity. Lyell was also an original investor in Outpace Bio.
  • Institute for Protein Design (UW)coreStrategic or Co-development PartnerOutpace collaborates with David Baker at the University of Washington Institute for Protein Design to access new machine learning algorithms for protein design capabilities. Baker's lab pioneered the ability to create new biological functions with de novo protein design.
  • Fred Hutch Cancer CentercoreStrategic or Co-development PartnerOutpace collaborates with Stanley Riddell at Fred Hutch Cancer Center, a leading expert in adoptive T cell therapy. Riddell co-designed the CD19-specific CAR used in trials that led to FDA-approved Breyanzi.
  • Memorial Sloan Kettering Cancer CenterminorStrategic or Co-development PartnerCollaboration with Prasad Adusumilli at MSKCC focused on solid tumor immunology and T-cell mediated immunotherapy development, particularly for thoracic malignancies and mesothelioma.
  • University of North CarolinaminorStrategic or Co-development PartnerCollaboration with Gianpietro Dotti at UNC Lineberger Comprehensive Cancer Center Immunotherapy Program, focusing on developing CAR-T cells for solid tumor treatment.

Scale indicators3 records

Recent moves9 records

Expansion highlights6 records

Outpace Bio competitors and assessment

Company assessment

Direct peers

  • Lyell Immunopharma: Lyell is Outpace's former parent company and current co-development partner on IL-12 cytokines. Both are clinical-stage cell therapy companies focused on solid tumors, sharing founding-team lineage and overlapping technology approaches to T cell persistence and exhaustion.
  • Iovance Biotherapeutics: Iovance is the leading commercial-stage tumor-infiltrating lymphocyte (TIL) therapy company for solid tumors, with FDA-approved Amtagvi for melanoma. It is the most relevant commercial benchmark for Outpace's solid tumor cell therapy ambitions and shares the autologous cell therapy manufacturing model.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies for solid tumors, with approved Tecelra for synovial sarcoma. Its SPEAR T-cell platform directly competes with Outpace's TCR-T program OPB-201 and shares the same solid tumor cell therapy development pathway.
  • Allogene Therapeutics: Allogene is a clinical-stage allogeneic CAR-T developer pursuing both hematologic and solid tumor indications. It is a comparable cell therapy developer with similar funding profile, clinical-stage pipeline, and focus on engineering T cells for cancer.
  • Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing for hematologic malignancies and solid tumors. As a clinical-stage engineered cell therapy company with similar funding trajectory, it is a directly comparable peer in modality and stage.
  • Fate Therapeutics: Fate Therapeutics develops off-the-shelf iPSC-derived NK and T cell therapies for cancer. Its engineered cell therapy pipeline and use of novel protein engineering approaches (chimeric antigen receptors, antigen receptors) make it a directly comparable peer in modality and platform strategy.
  • Sana Biotechnology: Sana Biotechnology is a clinical-stage cell therapy company developing both allogeneic CAR-T and in vivo gene editing approaches. Outpace's CSO Aaron Foster joined from Sana, and both companies share the engineering-driven approach to next-generation cell therapies.
  • Bellicum Pharmaceuticals: Bellicum developed GoCAR-T cell therapies for solid tumors with proprietary safety switches, sharing Outpace's emphasis on engineered safety controls and solid tumor focus. Several Outpace executives came from Bellicum, and the platforms address overlapping challenges.

Broad incumbents

  • CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company with the first FDA-approved CRISPR-based therapy (Casgevy) and a deep cell therapy pipeline. It is a broader, more advanced incumbent in the engineered cell therapy space with overlapping platform technologies.

Emerging players

  • Arsenal Biosciences: Arsenal Bio is a privately-held cell therapy company developing engineered T cell therapies for solid tumors using synthetic biology and machine learning. It is an emerging peer with overlapping platform ambitions in programmable cell therapy for cancer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Outpace Bio social profiles

Digital presence

Outpace Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Outpace Bio leadership team

Management profile

Number of profiles

Profiles7 records

Outpace Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Outpace Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Outpace Bio

What does Outpace Bio do?

Outpace Bio is a clinical-stage biotechnology company that uses AI-powered protein design to create engineered T cell therapies for solid tumors. The company combines five modular platform technologies (OUTSPACER, OUTSMART, OUTLAST, OUTSAFE/EGFRopt, and Logic Gated Targeting/CoLOCKR) into single cell therapy products, with lead program OPB-101 (mesothelin CAR-T) advancing through early clinical development for ovarian cancer.

Is Outpace Bio a public or private company?

Outpace Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Outpace Bio founded?

Outpace Bio was founded in 2021. It employs 51 to 100 people.

Where is Outpace Bio based?

Outpace Bio is headquartered in Seattle, United States, in the North America region.

How does Outpace Bio make money?

One revenue line is on record: cell Therapy Product Development.

Who are Outpace Bio's main competitors?

Direct peers on record are Lyell Immunopharma, Iovance Biotherapeutics, Adaptimmune Therapeutics, Allogene Therapeutics, Caribou Biosciences, Fate Therapeutics, Sana Biotechnology and Bellicum Pharmaceuticals. CRISPR Therapeutics is listed as a broad incumbent. Arsenal Biosciences is listed as an emerging player.

Does Outpace Bio have an API?

No public API is recorded for Outpace Bio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
RdworldonlineOpenFold3 preview: Apache-licensed co-folding modelThe OpenFold Consortium released OpenFold3, an Apache 2.0-licensed foundation model for predicting 3D protein structures and co-folding complexes with small-molecule ligands, nucleic acids, and other proteins, while Apheris simultaneously launched ApherisFold to enable secure deployment and benchmarking of the model within pharmaceutical environments. A federated initiative through the AI Structural Biology Network with five top-20 pharma companies leverages approximately five times more proprietary structural data than the Protein Data Bank, positioning OpenFold3 as a commercially permissive alternative to AlphaFold3. Early adopters including Novo Nordisk, Bayer Crop Science, Outpace Bio, and Cyrus Biotechnology are already deploying the model for applications ranging from small-molecule discovery to engineered cell-therapy circuits.ForbesHow Women VCs Are Shaping The Future Of HealthcareBlack Opal Ventures, a women-led healthcare venture firm founded by Dr. Tara Bishop and Eileen Tanghal, raised $55 million from institutional investors and $8 million from individual investors. The firm targets frontier technology and healthcare innovation, with portfolio companies like Outpace Bio and Conceivable. It aims to reshape an industry where women-founded startups receive less than 2% of U.S. venture funding.The Manila TimesOutpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingOutpace Bio will present new data on its lead programmed CAR T cell candidate OPB-101 at the 2024 SITC Annual Meeting in Houston. The poster highlights long-lived functional persistence and anti-tumor activity in xenograft models, with initial patient dosing targeted for 2025.GlobeNewswireOutpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingOutpace Bio will present new data on its lead programmed CAR T cell candidate OPB-101 at the 2024 SITC Annual Meeting in Houston. The poster shares updated preclinical efficacy results, including tumor re-implant and serial transfer studies showing long-lived persistence and anti-tumor activity. Initial patient dosing is targeted for 2025 for advanced ovarian cancer.AI InsiderOutpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical DevelopmentOutpace Bio raised $144 million in an oversubscribed Series B led by RA Capital Management, bringing total capital to $200 million. The funds will advance T cell product candidates for solid tumors, with lead program OPB-101 targeting clinical trials in 2025. Jake Simson, PhD, from RA Capital joined the board.GlobeNewswireOutpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical DevelopmentOutpace Bio raised $144 million in an oversubscribed Series B financing led by RA Capital Management. The funds will advance multiple T cell product candidates to early clinical proof-of-concept for solid tumors, with lead program OPB-101 on track for IND clearance and first dosing in 2025.HIT ConsultantOutpace Bio Secures $144M for AI-Powered Cell Therapy PlatformOutpace Bio raised $144M in a Series B led by RA Capital Management, with participation from Qatar Investment Authority and others. The company has now raised about $200M total. The funds will accelerate its AI-powered cell therapy platform, with its lead product OPB-101 on track for clinical trials in 2025.GlobeNewswireOutpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual MeetingOutpace Bio announced three poster presentations at the 2024 AACR Annual Meeting in San Diego, highlighting its lead program OPB-101, a mesothelin-specific CAR T cell therapeutic. The company reported complete tumor elimination in mouse models at doses as low as 50,000 cells, with an IND submission planned for Q4 2024.GlobeNewswireOutpace Bio to Present New Data on Tumor-restricted IL-12 Designed Leveraging OutSmart Technology to Enhance Solid Tumor T Cell Therapies at SITC 2023Outpace Bio will present new data on tumor-restricted IL-12 at SITC 2023, leveraging its OutSmart technology to enable localized cytokine activity. The technology aims to overcome safety risks of systemic IL-12 delivery while enhancing solid tumor T cell therapies. The data is being advanced under a collaboration with Lyell Immunopharma.